Arata Azuma

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 142 publications

Effect of nerandomilast on survival in patients with pulmonary fibrosis.

Effect of nerandomilast on survival in patients with pulmonary fibrosis.

Journal: The European respiratory journal

Published: February 13, 2026

Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.

Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.

Journal: The European respiratory journal

Published: September 10, 2025

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.

Journal: American journal of respiratory and critical care medicine

Published: June 13, 2025

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.

Journal: The New England journal of medicine

Published: May 19, 2025

Nerandomilast in Patients with Progressive Pulmonary Fibrosis.

Nerandomilast in Patients with Progressive Pulmonary Fibrosis.

Journal: The New England journal of medicine

Published: May 19, 2025

Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial.

Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial.

Journal: American journal of respiratory and critical care medicine

Published: May 15, 2025

Pulmonary sarcoidosis clinical trial end-points: a Delphi study.

Pulmonary sarcoidosis clinical trial end-points: a Delphi study.

Journal: The European respiratory journal

Published: May 07, 2025

Inflammatory and Coagulation Marker Changes in PMX-DHP-Treated COVID-19 Patients.

Inflammatory and Coagulation Marker Changes in PMX-DHP-Treated COVID-19 Patients.

Journal: Cureus

Published: January 25, 2025

Prognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030).

Prognostic prediction for newly diagnosed patients with idiopathic interstitial pneumonia: JIPS Registry (NEJ030).

Journal: Respiratory investigation

Published: December 18, 2024

Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON).

Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON).

Journal: BMC pulmonary medicine

Published: October 24, 2024

Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease.

Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease.

Journal: Arthritis research & therapy

Published: October 07, 2024

Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON.

Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON.

Journal: RMD open

Published: October 04, 2024

Showing 1-12 of 142

Last Updated: 09/26/2026